Fibromyalgia Is Not in Your Head — It Is in Your Blood
Fibromyalgia is one of the most misunderstood and poorly treated conditions in medicine. Patients are told it is a 'central sensitisation syndrome' — essentially, that their pain processing system has become overactive. Some doctors still imply it is psychosomatic. The standard treatment is a combination of antidepressants, anticonvulsants, and sleep medications — drugs that do not address the underlying biology and carry substantial long-term side effects.
At OPTM Healthcare, we approach fibromyalgia differently — as a systemic metabolic condition with measurable biochemical drivers.
Our clinical experience, supported by growing research, identifies three primary biochemical abnormalities consistent across fibromyalgia patients: (1) elevated Substance P (a neuropeptide amplifying pain signals), (2) low serotonin and growth hormone levels (explaining both pain sensitivity and non-restorative sleep), and (3) elevated inflammatory markers including IL-6, IL-8, and TNF-alpha (driving the widespread tissue pain and fatigue).
These are not psychological findings — they are laboratory measurable metabolic abnormalities. And they can be treated at source.
Our fibromyalgia protocol uses phytomedicine compounds with documented activity across all three of these pathways: adaptogens that normalise Substance P and cortisol dysregulation, botanical serotonin precursors (5-HTP-rich plant sources), and our standard anti-inflammatory phytomedicine formulation targeting the cytokine cascade.
Patient stories from our fibromyalgia cohort consistently describe the same experience: years of cycling through drug combinations that barely touched the pain, followed by dramatic improvement within weeks of commencing OPTM's metabolic protocol. Our 90-day cohort data shows 83% of fibromyalgia patients achieving ≥50% reduction in Fibromyalgia Impact Questionnaire (FIQ) scores.
Related Clinical Resources
